VT 1598
Alternative Names: NQP 1598; VT-1598Latest Information Update: 25 Jul 2023
At a glance
- Originator Mycovia Pharmaceuticals
- Developer Mycovia Pharmaceuticals; National Institute of Allergy and Infectious Diseases
- Class Antifungals; Small molecules; Tetrazoles
- Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P-450 enzyme system inhibitors; Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Candidiasis; Coccidioidomycosis; Cryptococcosis
Most Recent Events
- 25 Jul 2023 VT 1598 is still in phase I trials for Coccidioidomycosis (In volunteers) in USA (PO) (Mycovia Pharmaceuticals Pipeline, July 2023)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Coccidioidomycosis(In volunteers) in USA (PO)
- 22 Jun 2022 Phase-I clinical trials in Candidiasis in USA (PO) (Mycovia Pharmaceuticals pipeline, June 2022)